Sutro Biopharma Advances Cell-Free ADC Platform with Three IND Submissions Planned in 2026

Sutro Biopharma's cell-free conjugation platform is moving from preclinical validation into a multi-program clinical inflection point, with initial Phase 1 data for STRO-004, a Tissue Factor-targeting ADC, expected mid-2026 alongside two additional IND submissions before year-end. For bioprocessing and QA leads tracking next-generation ADC manufacturing, the pipeline's architecture, site-specific conjugation at defined drug-to-antibody ratios across DAR8 and DAR10 formats, signals upstream requirements that diverge materially from conventional stochastic conjugation workflows.

STRO-004 carries a DAR8 Topo1 payload and is currently in first-in-human Phase 1 dose-escalation in patients with advanced solid tumors. Preclinical data presented at the 2026 AACR Annual Meeting reported a highest non-severely toxic dose of 50 mg/kg in non-human primates, supporting a clinical starting dose of 1 mg/kg. The mid-2026 readout will cover safety, tolerability, pharmacokinetic exposure, and early activity, data that will also serve as a platform-level signal for Sutro's broader conjugation technology.

Two additional wholly-owned candidates are advancing in parallel. STRO-006, an ITGB6-targeting ADC with a DAR8 Topo1 payload, is progressing toward an IND submission in 2026. STRO-227, a DAR10 dual-payload ADC targeting PTK7, combines MMAE at DAR2 with a Topo1 payload at DAR8 within a single molecule, a format that places precise conjugation control at the center of process development and analytical characterization requirements.

On the collaboration side, the first partnered dual-payload immunostimulatory ADC developed under Sutro's agreement with Astellas has entered the clinic, with patient dosing underway for the TROP2-targeting program. That milestone triggered a $10 million payment to Sutro in April 2026. A second Astellas program remains in IND-enabling toxicology studies. For contract and clinical-stage manufacturers evaluating dual-payload iADC production, the Astellas program's transition to dosing represents one of the first clinical demonstrations of this format at scale.

Sutro reported $202.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026, with the runway extended into at least the second quarter of 2028 following a recent capital raise. The financial position supports continued process development and clinical operations across all three wholly-owned programs without near-term financing pressure.

The mid-2026 STRO-004 data readout will be the first clinical test of whether Sutro's cell-free platform can deliver the safety and PK consistency that site-specific conjugation at DAR8 is designed to produce.

Source: Sutro Biopharma, Inc. press release via GlobeNewswire, May 14, 2026.